• Bayer AG swung to net income of €2.76 billion as EBIT rose 51.8% to €3.53 billion.
• Net sales fell 2.4% to €13.41 billion, while EBITDA before special items increased 9% to €4.45 billion.
• Free cash flow widened to an outflow of €2.32 billion, while net financial debt climbed to €32.52 billion.
• Crop Science net sales slipped 0.3% to €7.56 billion, while Pharmaceuticals net sales dropped 6.6% to €4.25 billion.
• Outlook for 2026 was confirmed on a currency-adjusted basis; Perfuse Therapeutics acquisition agreement carried total potential value up to US$2.45 billion, while Avelox divestment generated €250 million in other operating income.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.